Core Advantage: Triple-layered protection ensures absolute security.
1. A groundbreaking breakthrough in inactivation efficacy

High‑temperature, high‑pressure precision synergy: Employing a double‑layer FBE anti‑corrosion jacket and multi‑section flow‑diverting coils, the penetration efficiency of saturated steam is improved by 40%, and the temperature uniformity within the chamber at 121°C reaches ±0.5°C, ensuring a ≥6‑log reduction in the survival rate of recalcitrant pathogens such as Bacillus stearothermophilus.
Chemical–physical dual-mode inactivation: Optionally equipped with a hydrogen peroxide (VHP) vaporization system or an acid–alkali reagent injection unit, enabling the thorough degradation of prions, heat‑resistant endotoxins, and other challenging contaminants, with residual DNA/RNA fragments ≤ 10 pg/mL.
2. Biological Sealing and Protection System

Negative-pressure double-seal sealing mechanism: The vessel is manufactured using laser-welded integral forming technology (with a weld porosity of less than 0.01%), coupled with a magnetic‑drive agitator sealing system to eliminate the risk of mechanical shaft seal leakage. The chamber maintains a constant negative pressure of **–30 Pa**, and, in conjunction with a HEPA exhaust gas filtration system, ensures zero aerosol leakage.
Intelligent Pressure‑Relief Protection System: Equipped with a pressure‑sensing diaphragm rupture‑monitoring module, it automatically shuts off the feed line and activates emergency cooling when the inner vessel experiences abnormal pressure buildup, thereby mitigating the risk of tank rupture.
3. End-to-end digital traceability

Equipped with an industrial IoT control terminal, it records in real time key parameters such as temperature–pressure–time (T/P/t) curves and inactivant concentration, and generates electronic signature‑compliant reports in accordance with 21 CFR Part 11.
Supports 3D dynamic heat‑map analysis, automatically identifies cold‑spot areas and recommends deactivation protocols, and provides audit‑trail data storage for ≥10 years.
Deep Applications Across Multiple Industries: From the Laboratory to Industrialization
Biopharmaceuticals: Safeguarding the Safety Chain of Vaccines and Blood Products
A national-level vaccine manufacturer has adopted the Haoran fully automated cell‑culture inactivation platform to inactivate rabies virus in Vero cell‑based substrates, reducing the viral titer to ≤0.1 LD₅₀/mL and achieving WHO prequalification.
Blood products facilities have implemented a low-temperature plasma inactivation system (operating at 37°C), which, while preserving the activity of coagulation factors, achieves an HBV/HCV viral inactivation efficiency of ≥99.9999%.
Hazardous Chemicals: Achieving Harmless Transformation of High-Risk Waste
Leading agrochemical companies have deployed sets of inactivation tanks for organophosphorus‑containing wastewater, employing an alkaline hydrolysis process (pH > 12, 80°C) to degrade the highly toxic methyl parathion into biodegradable small molecules, achieving a toxicity reduction rate of 99.8%.
The semiconductor factory employs a closed-loop inactivation system for cyanide-containing wastewater, which catalyzes the conversion of cyanide (CN⁻) into non-toxic nitrogen gas (N₂) and carbon dioxide (CO₂) using hypochlorite. The treatment capacity reaches 5 tons per day.
Microbial Research: Strengthening the Laboratory Biosafety Barrier
The BSL‑3 laboratory is equipped with a double‑door pass‑through autoclave for inactivating mycobacterial cultures, employing an intensive sterilization protocol of 135°C for 45 minutes. Exhaust gases are subjected to two‑stage incineration, ensuring that emissions comply with ISO Class 5 cleanliness standards.
Gene-editing companies use CRISPR‑based inactivation workstations to achieve complete degradation of plasmid DNA via a combined UV–ozone treatment, thereby preventing the unintended release of genetically engineered microorganisms.
Food Industry: Unlocking the Challenges of Allergens and Toxins
Dairy companies utilize a β‑lactoglobulin‑specific inactivation tank and a tailored enzymatic hydrolysis process to disrupt allergenic protein epitopes while preserving 80% of lactoferrin activity, thereby meeting the needs of consumers with food allergies.
A grain and oil processing plant has commissioned an aflatoxin-degradation system that uses ozone micro‑ and nano‑bubble technology to convert B1 toxin into the non‑toxic B2a, with residual levels below 1 ppb.